Thetford Mines, August 28, 2018 – KDA Group Inc. (TSXV: KDA) (“KDA Group” or the “Corporation”) announced on June 1st, 2018 an agreement with ZoomMed Inc. (TSXV: ZMD) (“ZoomMed”) whereby KDA Group could have obtained the rights to distribute, under a non-exclusive license, the ZRx Prescriber developed by ZoomMed in the United States.
- KDA Group completes debt settlement
- KDA Group announces appointment of new Director, Mr. Stan Bharti
- KDA Group has signed a letter of intent for the acquisition of CONSUTLANDGROW
- KDA Group annouces definitive closing of private placement
- KDA Group annouces the appointment of Dr Giuseppe D’Aprano as Chief Scientific Officer